The Cigna Group (CI)

Cigna: Looks More Interesting Here Than UnitedHealth Group

Cigna offers a lower-risk profile after selling its Medicare business, avoiding Medicare headwinds impacting peers like UnitedHealth Group. However, the stock price has fallen alongside UNH. Recent earnings were strong, guidance was affirmed, and valuation is attractive, with Wall Street seeing up to 35% upside potential. Risks remain from medical inflation and PBM regulatory scrutiny, but Cigna's business mix provides more pricing power and operational flexibility than UNH.

Why Cigna (CI) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes?

Cigna's 2nd quarter profits beat Wall Street's expectations

Cigna beat Wall Street estimates for second-quarter profit on Thursday, helped by strength in its pharmacy benefit management business.

Cigna Q2 Earnings Beat Estimates on Higher Specialty Volumes

CI's Q2 earnings benefit from strong Evernorth Health Services unit, offsetting customer losses and rising costs. It continues to expect 2025 adjusted EPS at a minimum of $29.60.

Cigna Sees Elevated Cost Trends To Continue Into Next Year

The Cigna Group (CI) Q2 2025 Earnings Call Transcript

The Cigna Group (NYSE:CI ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Ann M. Dennison - Executive VP & CFO Brian C.

Cigna (CI) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cigna to Report Q2 Earnings: Can Evernorth Offset Healthcare Weakness?

CI's Q2 results are likely to hinge on Evernorth's growth as core healthcare revenues and premiums face steep declines.

3 Dividend Growth Stocks That Will Deliver Meaty Returns After 5 Years

Sufficient earnings growth to continually increase dividends at a comfortably low payout ratio that also accommodates expansion capex is an excellent signal for strong upside potential.

10 Undervalued Dividend Growth Stocks: July 2025

I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the top ten stocks for consideration. I use two valuation screens, one based on my fair value estimate and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics.

Most Managed Care Insurers Expected To See Q2 2025 Drops In Revenue, Net Income

A majority of publicly traded US health insurers are expected to post QoQ declines in revenue and net income in Q2, according to an S&P Global Market Intelligence analysis of sell-side analyst forecasts. Of the eight largest publicly traded US managed care insurers, all but two — UnitedHealth Group and Alignment Healthcare — are projected to report lower revenue compared with Q1 2025, while all eight are forecast to log higher revenue than Q2 2024. In Q2, all eight of the largest publicly traded US managed care insurers, except The Cigna Group, are expected to log lower net income sequentially, …

Why Cigna (CI) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes?

Cigna Group: Is The Value Real Or Are Investors Just Stuck In Neutral?

The Cigna Group's risk/reward is balanced after a rebound; I rate it Hold—worth keeping if owned, but not a compelling buy right now. The Evernorth pharmacy benefits arm drives growth, but regulatory risk and insurance challenges keep me cautious until a clearer catalyst emerges. Cigna's fundamentals are solid—growing earnings, strong cash flow, shareholder returns—but the stock is fairly valued versus peers, not a bargain.

Cigna: Price Pullback Is A Great Opportunity

Cigna trades at a significant discount to the S&P 500, offering a higher yield and faster dividend growth, making it attractive for total return investors. CI's robust earnings growth is fueled by its Evernorth and Healthcare segments, with strong results and promising exposure to the booming GLP-1 drug market. Management targets 10-14% annual EPS growth, supported by aggressive share buybacks and a safe, growing dividend nearly double the S&P 500 yield.

UnitedHealth vs. Cigna: Which Insurer to Buy Amid Sector Turmoil?

CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.

Cigna Expands Coverage With RhinAer & Enhances Rhinitis Treatment

CI to cover RhinAer for chronic rhinitis starting Sept. 15, expanding access to a minimally invasive, office-based treatment.

Cigna Enables Coverage for RhinAer®

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna's list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patien.

4 HMO Stocks Set to Thrive From Steady Premium Flows, M&A Strategy

Rising premiums, ongoing technological innovation and the growing demand for Medicare plans are anticipated to propel the performance of the Zacks Medical-HMO industry players. CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.

Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst

Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst.

Cigna: Valuation Discount To Historical And Sector Averages Persists

Cigna has transformed into a diversified healthcare platform, focusing on high-margin corporate insurance and pharmacy services while divesting non-core assets. Despite margin pressures, Cigna's service-driven model delivers strong revenue growth, stable cash flows, and resilient EPS, supported by robust buybacks and dividend increases. My DCF analysis shows Cigna is undervalued, trading at a deep discount to sector peers, with an 11%+ upside and limited downside risk even in conservative scenarios.

Here's Why You Should Hold Cigna Stock in Your Portfolio for Now

CI gains 14.7% YTD as Evernorth and Cigna Healthcare drive growth, but rising expenses and debt pose challenges.

Cigna Adds Kerecis Intact Fish-Skin Grafts to Coverage Policy

ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)-- #kerecis--Cigna Insurance Company now includes Kerecis products in its medical coverage policy for the treatment of diabetic foot ulcers.

UnitedHealth is Imploding: 3 Stocks That Could Eat Its Lunch

The abrupt departure of UnitedHealth (NYSE:UNH) CEO Andrew Witty this week has sent shockwaves through an already tumultuous healthcare sector.

Cigna Q1 Earnings Beat Estimates on Evernorth Health Strength

CI increases adjusted earnings guidance for 2025 to $29.60 per share from the previous estimate of $29.50.

The Cigna Group (CI) Q1 2025 Earnings Call Transcript

The Cigna Group (NYSE:CI ) Q1 2025 Earnings Conference Call May 2, 2025 8:30 AM ET Company Participants Ralph Giacobbe - Senior Vice President, Investor Relations David Cordani - Chairman and Chief Executive Officer Brian Evanko - President and Chief Operating Officer Ann Dennison - Executive Vice President and Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan A.J. Rice - UBS Justin Lake - Wolf Research Charles Rhyee - TD Cowen Ann Hynes - Mizuho Securities Andrew Mok - Barclays Erin Wright - Morgan Stanley Joshua Raskin - Nephron Research George Hill - Deutsche Bank Operator Ladies and …

Cigna (CI) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Will Declining Medical Customers Affect Cigna's Q1 Earnings?

CI's first-quarter results are likely to have benefited from growing pharmacy revenues and fees.

The Cigna Group Foundation Commits Additional $1M to Boys & Girls Clubs of America to Support Youth Mental Health

BLOOMFIELD, Conn. , April 22, 2025 /PRNewswire/ -- As part of The Cigna Group's (NYSE: CI) multiyear commitment to improve youth mental health, The Cigna Group Foundation announced a $1 million contribution over the next two years to Boys & Girls Clubs of America.

Canada launches probe into Cigna's Express Scripts

Canada's Competition Bureau said on Friday it has launched an investigation into Cigna's pharmacy benefit management unit Express Scripts.

Cigna: Fewer Protests, More Potential

Cigna's strong growth, favorable valuation, and shareholder policies justify a "buy" rating, outperforming the S&P500 with a 37% return since May 2023. The integration of insurance with pharmacy benefit management, particularly through Evernorth, enhances cost control and customer retention, driving significant revenue growth. Despite rising medical costs and public dissatisfaction with insurers, Cigna's strategic focus on commercial health plans and PBMs mitigates risks and supports future growth.